0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Viral Vector-Based Gene Therapy Drugs Market Research Report 2024
Published Date: April 2024
|
Report Code: QYRE-Auto-28A16702
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Viral Vector Based Gene Therapy Drugs Market Research Report 2024
BUY CHAPTERS

Global Viral Vector-Based Gene Therapy Drugs Market Research Report 2024

Code: QYRE-Auto-28A16702
Report
April 2024
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Viral Vector-Based Gene Therapy Drugs Market

Viral vector-based gene therapy drugs are pharmaceutical products that use viral vectors to deliver therapeutic genes into target cells for the treatment of genetic disorders or diseases. These drugs typically contain modified viruses as vectors to efficiently and safely transfer genetic material into the cells of patients, aiming to correct genetic mutations or induce specific therapeutic effects.
The global Viral Vector-Based Gene Therapy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Viral Vector-Based Gene Therapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Viral Vector-Based Gene Therapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Viral Vector-Based Gene Therapy Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Viral Vector-Based Gene Therapy Drugs include GSK, MolMed, GILD, JW Therapeutics, Sibiono, Latima, Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Viral Vector-Based Gene Therapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector-Based Gene Therapy Drugs.
The Viral Vector-Based Gene Therapy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vector-Based Gene Therapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector-Based Gene Therapy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Viral Vector-Based Gene Therapy Drugs Market Report

Report Metric Details
Report Name Viral Vector-Based Gene Therapy Drugs Market
Segment by Type
  • Retroviral Vector
  • Adenovirus Vector
  • Lentiviral Vector
  • Others
Segment by Application
  • Hospital
  • Diagnostic and Testing Laboratories
  • Academic and Research Organizations
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company GSK, MolMed, GILD, JW Therapeutics, Sibiono, Latima, Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, BMS, Orchard Therapeutics, Shanghai Sunway Biotech, uniQure, Spark Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Viral Vector-Based Gene Therapy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Viral Vector-Based Gene Therapy Drugs Market report?

Ans: The main players in the Viral Vector-Based Gene Therapy Drugs Market are GSK, MolMed, GILD, JW Therapeutics, Sibiono, Latima, Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, BMS, Orchard Therapeutics, Shanghai Sunway Biotech, uniQure, Spark Therapeutics

What are the Application segmentation covered in the Viral Vector-Based Gene Therapy Drugs Market report?

Ans: The Applications covered in the Viral Vector-Based Gene Therapy Drugs Market report are Hospital, Diagnostic and Testing Laboratories, Academic and Research Organizations, Others

What are the Type segmentation covered in the Viral Vector-Based Gene Therapy Drugs Market report?

Ans: The Types covered in the Viral Vector-Based Gene Therapy Drugs Market report are Retroviral Vector, Adenovirus Vector, Lentiviral Vector, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Retroviral Vector
1.2.3 Adenovirus Vector
1.2.4 Lentiviral Vector
1.2.5 Others
1.3 Market by Application
1.3.1 Global Viral Vector-Based Gene Therapy Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Diagnostic and Testing Laboratories
1.3.4 Academic and Research Organizations
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vector-Based Gene Therapy Drugs Market Perspective (2019-2030)
2.2 Global Viral Vector-Based Gene Therapy Drugs Growth Trends by Region
2.2.1 Global Viral Vector-Based Gene Therapy Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Viral Vector-Based Gene Therapy Drugs Historic Market Size by Region (2019-2024)
2.2.3 Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Region (2025-2030)
2.3 Viral Vector-Based Gene Therapy Drugs Market Dynamics
2.3.1 Viral Vector-Based Gene Therapy Drugs Industry Trends
2.3.2 Viral Vector-Based Gene Therapy Drugs Market Drivers
2.3.3 Viral Vector-Based Gene Therapy Drugs Market Challenges
2.3.4 Viral Vector-Based Gene Therapy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vector-Based Gene Therapy Drugs Players by Revenue
3.1.1 Global Top Viral Vector-Based Gene Therapy Drugs Players by Revenue (2019-2024)
3.1.2 Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Viral Vector-Based Gene Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Viral Vector-Based Gene Therapy Drugs Revenue
3.4 Global Viral Vector-Based Gene Therapy Drugs Market Concentration Ratio
3.4.1 Global Viral Vector-Based Gene Therapy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vector-Based Gene Therapy Drugs Revenue in 2023
3.5 Global Key Players of Viral Vector-Based Gene Therapy Drugs Head office and Area Served
3.6 Global Key Players of Viral Vector-Based Gene Therapy Drugs, Product and Application
3.7 Global Key Players of Viral Vector-Based Gene Therapy Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vector-Based Gene Therapy Drugs Breakdown Data by Type
4.1 Global Viral Vector-Based Gene Therapy Drugs Historic Market Size by Type (2019-2024)
4.2 Global Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Type (2025-2030)
5 Viral Vector-Based Gene Therapy Drugs Breakdown Data by Application
5.1 Global Viral Vector-Based Gene Therapy Drugs Historic Market Size by Application (2019-2024)
5.2 Global Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Viral Vector-Based Gene Therapy Drugs Market Size (2019-2030)
6.2 North America Viral Vector-Based Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Viral Vector-Based Gene Therapy Drugs Market Size by Country (2019-2024)
6.4 North America Viral Vector-Based Gene Therapy Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Viral Vector-Based Gene Therapy Drugs Market Size (2019-2030)
7.2 Europe Viral Vector-Based Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Viral Vector-Based Gene Therapy Drugs Market Size by Country (2019-2024)
7.4 Europe Viral Vector-Based Gene Therapy Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size (2019-2030)
8.2 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Viral Vector-Based Gene Therapy Drugs Market Size (2019-2030)
9.2 Latin America Viral Vector-Based Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Viral Vector-Based Gene Therapy Drugs Market Size by Country (2019-2024)
9.4 Latin America Viral Vector-Based Gene Therapy Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size (2019-2030)
10.2 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Viral Vector-Based Gene Therapy Drugs Introduction
11.1.4 GSK Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.1.5 GSK Recent Development
11.2 MolMed
11.2.1 MolMed Company Details
11.2.2 MolMed Business Overview
11.2.3 MolMed Viral Vector-Based Gene Therapy Drugs Introduction
11.2.4 MolMed Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.2.5 MolMed Recent Development
11.3 GILD
11.3.1 GILD Company Details
11.3.2 GILD Business Overview
11.3.3 GILD Viral Vector-Based Gene Therapy Drugs Introduction
11.3.4 GILD Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.3.5 GILD Recent Development
11.4 JW Therapeutics
11.4.1 JW Therapeutics Company Details
11.4.2 JW Therapeutics Business Overview
11.4.3 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Introduction
11.4.4 JW Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.4.5 JW Therapeutics Recent Development
11.5 Sibiono
11.5.1 Sibiono Company Details
11.5.2 Sibiono Business Overview
11.5.3 Sibiono Viral Vector-Based Gene Therapy Drugs Introduction
11.5.4 Sibiono Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.5.5 Sibiono Recent Development
11.6 Latima
11.6.1 Latima Company Details
11.6.2 Latima Business Overview
11.6.3 Latima Viral Vector-Based Gene Therapy Drugs Introduction
11.6.4 Latima Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.6.5 Latima Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Viral Vector-Based Gene Therapy Drugs Introduction
11.7.4 Novartis Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 Bluebird Bio
11.8.1 Bluebird Bio Company Details
11.8.2 Bluebird Bio Business Overview
11.8.3 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Introduction
11.8.4 Bluebird Bio Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.8.5 Bluebird Bio Recent Development
11.9 Thermo Fisher Scientific
11.9.1 Thermo Fisher Scientific Company Details
11.9.2 Thermo Fisher Scientific Business Overview
11.9.3 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Introduction
11.9.4 Thermo Fisher Scientific Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.9.5 Thermo Fisher Scientific Recent Development
11.10 Intas
11.10.1 Intas Company Details
11.10.2 Intas Business Overview
11.10.3 Intas Viral Vector-Based Gene Therapy Drugs Introduction
11.10.4 Intas Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.10.5 Intas Recent Development
11.11 BMS
11.11.1 BMS Company Details
11.11.2 BMS Business Overview
11.11.3 BMS Viral Vector-Based Gene Therapy Drugs Introduction
11.11.4 BMS Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.11.5 BMS Recent Development
11.12 Orchard Therapeutics
11.12.1 Orchard Therapeutics Company Details
11.12.2 Orchard Therapeutics Business Overview
11.12.3 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Introduction
11.12.4 Orchard Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.12.5 Orchard Therapeutics Recent Development
11.13 Shanghai Sunway Biotech
11.13.1 Shanghai Sunway Biotech Company Details
11.13.2 Shanghai Sunway Biotech Business Overview
11.13.3 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Introduction
11.13.4 Shanghai Sunway Biotech Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.13.5 Shanghai Sunway Biotech Recent Development
11.14 uniQure
11.14.1 uniQure Company Details
11.14.2 uniQure Business Overview
11.14.3 uniQure Viral Vector-Based Gene Therapy Drugs Introduction
11.14.4 uniQure Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.14.5 uniQure Recent Development
11.15 Spark Therapeutics
11.15.1 Spark Therapeutics Company Details
11.15.2 Spark Therapeutics Business Overview
11.15.3 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Introduction
11.15.4 Spark Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
11.15.5 Spark Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of Retroviral Vector
 Table 3. Key Players of Adenovirus Vector
 Table 4. Key Players of Lentiviral Vector
 Table 5. Key Players of Others
 Table 6. Global Viral Vector-Based Gene Therapy Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 7. Global Viral Vector-Based Gene Therapy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 8. Global Viral Vector-Based Gene Therapy Drugs Market Size by Region (2019-2024) & (US$ Million)
 Table 9. Global Viral Vector-Based Gene Therapy Drugs Market Share by Region (2019-2024)
 Table 10. Global Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 11. Global Viral Vector-Based Gene Therapy Drugs Market Share by Region (2025-2030)
 Table 12. Viral Vector-Based Gene Therapy Drugs Market Trends
 Table 13. Viral Vector-Based Gene Therapy Drugs Market Drivers
 Table 14. Viral Vector-Based Gene Therapy Drugs Market Challenges
 Table 15. Viral Vector-Based Gene Therapy Drugs Market Restraints
 Table 16. Global Viral Vector-Based Gene Therapy Drugs Revenue by Players (2019-2024) & (US$ Million)
 Table 17. Global Viral Vector-Based Gene Therapy Drugs Market Share by Players (2019-2024)
 Table 18. Global Top Viral Vector-Based Gene Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Gene Therapy Drugs as of 2023)
 Table 19. Ranking of Global Top Viral Vector-Based Gene Therapy Drugs Companies by Revenue (US$ Million) in 2023
 Table 20. Global 5 Largest Players Market Share by Viral Vector-Based Gene Therapy Drugs Revenue (CR5 and HHI) & (2019-2024)
 Table 21. Global Key Players of Viral Vector-Based Gene Therapy Drugs, Headquarters and Area Served
 Table 22. Global Key Players of Viral Vector-Based Gene Therapy Drugs, Product and Application
 Table 23. Global Key Players of Viral Vector-Based Gene Therapy Drugs, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Viral Vector-Based Gene Therapy Drugs Market Size by Type (2019-2024) & (US$ Million)
 Table 26. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Type (2019-2024)
 Table 27. Global Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 28. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Type (2025-2030)
 Table 29. Global Viral Vector-Based Gene Therapy Drugs Market Size by Application (2019-2024) & (US$ Million)
 Table 30. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Application (2019-2024)
 Table 31. Global Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 32. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Application (2025-2030)
 Table 33. North America Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 34. North America Viral Vector-Based Gene Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)
 Table 35. North America Viral Vector-Based Gene Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)
 Table 36. Europe Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 37. Europe Viral Vector-Based Gene Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)
 Table 38. Europe Viral Vector-Based Gene Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)
 Table 39. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 40. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Region (2019-2024) & (US$ Million)
 Table 41. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Region (2025-2030) & (US$ Million)
 Table 42. Latin America Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 43. Latin America Viral Vector-Based Gene Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Viral Vector-Based Gene Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)
 Table 45. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 46. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)
 Table 47. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)
 Table 48. GSK Company Details
 Table 49. GSK Business Overview
 Table 50. GSK Viral Vector-Based Gene Therapy Drugs Product
 Table 51. GSK Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 52. GSK Recent Development
 Table 53. MolMed Company Details
 Table 54. MolMed Business Overview
 Table 55. MolMed Viral Vector-Based Gene Therapy Drugs Product
 Table 56. MolMed Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 57. MolMed Recent Development
 Table 58. GILD Company Details
 Table 59. GILD Business Overview
 Table 60. GILD Viral Vector-Based Gene Therapy Drugs Product
 Table 61. GILD Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 62. GILD Recent Development
 Table 63. JW Therapeutics Company Details
 Table 64. JW Therapeutics Business Overview
 Table 65. JW Therapeutics Viral Vector-Based Gene Therapy Drugs Product
 Table 66. JW Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 67. JW Therapeutics Recent Development
 Table 68. Sibiono Company Details
 Table 69. Sibiono Business Overview
 Table 70. Sibiono Viral Vector-Based Gene Therapy Drugs Product
 Table 71. Sibiono Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 72. Sibiono Recent Development
 Table 73. Latima Company Details
 Table 74. Latima Business Overview
 Table 75. Latima Viral Vector-Based Gene Therapy Drugs Product
 Table 76. Latima Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 77. Latima Recent Development
 Table 78. Novartis Company Details
 Table 79. Novartis Business Overview
 Table 80. Novartis Viral Vector-Based Gene Therapy Drugs Product
 Table 81. Novartis Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 82. Novartis Recent Development
 Table 83. Bluebird Bio Company Details
 Table 84. Bluebird Bio Business Overview
 Table 85. Bluebird Bio Viral Vector-Based Gene Therapy Drugs Product
 Table 86. Bluebird Bio Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 87. Bluebird Bio Recent Development
 Table 88. Thermo Fisher Scientific Company Details
 Table 89. Thermo Fisher Scientific Business Overview
 Table 90. Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Product
 Table 91. Thermo Fisher Scientific Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 92. Thermo Fisher Scientific Recent Development
 Table 93. Intas Company Details
 Table 94. Intas Business Overview
 Table 95. Intas Viral Vector-Based Gene Therapy Drugs Product
 Table 96. Intas Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 97. Intas Recent Development
 Table 98. BMS Company Details
 Table 99. BMS Business Overview
 Table 100. BMS Viral Vector-Based Gene Therapy Drugs Product
 Table 101. BMS Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 102. BMS Recent Development
 Table 103. Orchard Therapeutics Company Details
 Table 104. Orchard Therapeutics Business Overview
 Table 105. Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Product
 Table 106. Orchard Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 107. Orchard Therapeutics Recent Development
 Table 108. Shanghai Sunway Biotech Company Details
 Table 109. Shanghai Sunway Biotech Business Overview
 Table 110. Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Product
 Table 111. Shanghai Sunway Biotech Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 112. Shanghai Sunway Biotech Recent Development
 Table 113. uniQure Company Details
 Table 114. uniQure Business Overview
 Table 115. uniQure Viral Vector-Based Gene Therapy Drugs Product
 Table 116. uniQure Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 117. uniQure Recent Development
 Table 118. Spark Therapeutics Company Details
 Table 119. Spark Therapeutics Business Overview
 Table 120. Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Product
 Table 121. Spark Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2019-2024) & (US$ Million)
 Table 122. Spark Therapeutics Recent Development
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Viral Vector-Based Gene Therapy Drugs Picture
 Figure 2. Global Viral Vector-Based Gene Therapy Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Viral Vector-Based Gene Therapy Drugs Market Share by Type: 2023 VS 2030
 Figure 4. Retroviral Vector Features
 Figure 5. Adenovirus Vector Features
 Figure 6. Lentiviral Vector Features
 Figure 7. Others Features
 Figure 8. Global Viral Vector-Based Gene Therapy Drugs Market Size by Application (2024-2030) & (US$ Million)
 Figure 9. Global Viral Vector-Based Gene Therapy Drugs Market Share by Application: 2023 VS 2030
 Figure 10. Hospital Case Studies
 Figure 11. Diagnostic and Testing Laboratories Case Studies
 Figure 12. Academic and Research Organizations Case Studies
 Figure 13. Others Case Studies
 Figure 14. Viral Vector-Based Gene Therapy Drugs Report Years Considered
 Figure 15. Global Viral Vector-Based Gene Therapy Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 16. Global Viral Vector-Based Gene Therapy Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 17. Global Viral Vector-Based Gene Therapy Drugs Market Share by Region: 2023 VS 2030
 Figure 18. Global Viral Vector-Based Gene Therapy Drugs Market Share by Players in 2023
 Figure 19. Global Top Viral Vector-Based Gene Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Gene Therapy Drugs as of 2023)
 Figure 20. The Top 10 and 5 Players Market Share by Viral Vector-Based Gene Therapy Drugs Revenue in 2023
 Figure 21. North America Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 22. North America Viral Vector-Based Gene Therapy Drugs Market Share by Country (2019-2030)
 Figure 23. United States Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 24. Canada Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 25. Europe Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 26. Europe Viral Vector-Based Gene Therapy Drugs Market Share by Country (2019-2030)
 Figure 27. Germany Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 28. France Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 29. U.K. Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. Italy Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. Russia Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 32. Nordic Countries Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 33. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Share by Region (2019-2030)
 Figure 35. China Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 36. Japan Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 37. South Korea Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 38. Southeast Asia Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 39. India Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 40. Australia Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 41. Latin America Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 42. Latin America Viral Vector-Based Gene Therapy Drugs Market Share by Country (2019-2030)
 Figure 43. Mexico Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 44. Brazil Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 45. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Share by Country (2019-2030)
 Figure 47. Turkey Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 48. Saudi Arabia Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 49. UAE Viral Vector-Based Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 50. GSK Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 51. MolMed Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 52. GILD Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 53. JW Therapeutics Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 54. Sibiono Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 55. Latima Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 56. Novartis Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 57. Bluebird Bio Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 58. Thermo Fisher Scientific Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 59. Intas Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 60. BMS Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 61. Orchard Therapeutics Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 62. Shanghai Sunway Biotech Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 63. uniQure Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 64. Spark Therapeutics Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2019-2024)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS